- Home
- OSRH vs NLSP Comparison
OSRH vs NLSP Comparison
Compare OSRH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSRH
- NLSP
- Stock Information
- Founded
- OSRH N/A
- NLSP 2015
- Country
- OSRH United States
- NLSP Switzerland
- Employees
- OSRH N/A
- NLSP N/A
- Industry
- OSRH
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- OSRH
- NLSP Health Care
- Exchange
- OSRH Nasdaq
- NLSP Nasdaq
- Market Cap
- OSRH 13.2M
- NLSP 12.4M
- IPO Year
- OSRH N/A
- NLSP 2021
- Fundamental
- Price
- OSRH $0.60
- NLSP $1.86
- Analyst Decision
- OSRH
- NLSP
- Analyst Count
- OSRH 0
- NLSP 0
- Target Price
- OSRH N/A
- NLSP N/A
- AVG Volume (30 Days)
- OSRH 988.8K
- NLSP 940.1K
- Earning Date
- OSRH 11-24-2025
- NLSP 10-06-2025
- Dividend Yield
- OSRH N/A
- NLSP N/A
- EPS Growth
- OSRH N/A
- NLSP N/A
- EPS
- OSRH N/A
- NLSP N/A
- Revenue
- OSRH $104,735.00
- NLSP N/A
- Revenue This Year
- OSRH N/A
- NLSP N/A
- Revenue Next Year
- OSRH N/A
- NLSP N/A
- P/E Ratio
- OSRH N/A
- NLSP N/A
- Revenue Growth
- OSRH N/A
- NLSP N/A
- 52 Week Low
- OSRH $0.45
- NLSP $1.30
- 52 Week High
- OSRH $13.40
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- OSRH 45.43
- NLSP 42.05
- Support Level
- OSRH $0.53
- NLSP $1.76
- Resistance Level
- OSRH $0.76
- NLSP $2.15
- Average True Range (ATR)
- OSRH 0.05
- NLSP 0.21
- MACD
- OSRH 0.00
- NLSP -0.02
- Stochastic Oscillator
- OSRH 35.47
- NLSP 12.14
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.